Recent Research on Global Systemic Psoriasis Therapeutics Market 2016-2020

Report : Global Systemic Psoriasis Therapeutics Market 2016-2020 is a new market research publication announced by Reportstack.

Report Outline: Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years).

Psoriasis is more prevalent among Caucasians compared to African-Americans. According to a World Health Organization (WHO) document of 2015, the global prevalence of psoriasis is approximately 2%-3%. However, it is approximately 4.6% in developed countries. In addition, the risk of an individual getting diagnosed with psoriasis is 41% if both parents have psoriasis, 14% in case one parent is affected, and 6% if a sibling has psoriasis.

For detailed report with TOC, please click here ​Global Systemic Psoriasis Therapeutics Market 2016-2020.

Market Growth: The global systemic psoriasis therapeutics market is expected to grow at a CAGR of 9.41% during the period 2016-2020.

Key vendors 
• AbbVie
• Johnson & Johnson
• Celgene
• Amgen
• Pfizer

Other prominent vendors 
• AbGenomics
• Almirall 
• Anacor Pharmaceuticals
• ApoPharma
• Astellas Pharma
• AstraZeneca
• Aurinia Pharmaceuticals
• Biocon
• Biogen Idec
• Biotest 
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Can-Fite BioPharma
• Cellceutix Corporation
• Coherus Biosciences
• Creabilis
• Crescendo Biologics
• Delenex Therapeutics
• Dermira
• Eli Lilly
• F. Hoffmann-La Roche
• Forward Pharma
• G & W Laboratories
• GlaxoSmithKline
• Idera Pharmaceuticals
• Incyte 
• Kadmon 
• kinetabio
• KPI Therapeutics
• Kyowa Hakko Kirin
• LEO Pharma
• Maruho
• Merck
• Mitsubishi Tanabe Pharma 
• Moleculin
• MorphoSys
• Novartis
• Prism Pharma 
• Promius Pharma
• Prothena Biosciences 
• Provectus Biopharmaceuticals
• Sandoz
• Sun Pharmaceuticals
• Takeda Pharmaceuticals
• Taro Pharmaceuticals
• TFS 
• Valeant Pharmaceuticals
• VBL Therapeutics
• XenoPort
• Ziarco Pharma

Regions Covered: 

• Americas

Companies Mentioned

AbbVie, Johnson & Johnson, Celgene, Amgen, Pfizer, AbGenomics, Almirall, Anacor Pharmaceuticals, ApoPharma, Astellas Pharma, AstraZeneca, Aurinia Pharmaceuticals, Biocon, Biogen Idec, Biotest, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite BioPharma, Cellceutix Corporation, Coherus Biosciences, Creabilis, Crescendo Biologics, Delenex Therapeutics, Dermira, Eli Lilly, F. Hoffmann-La Roche, Forward Pharma, G & W Laboratories, GlaxoSmithKline, Idera Pharmaceuticals, Incyte Corporation, Kadmon, kinetabio, KPI Therapeutics, Kyowa Hakko Kirin, LEO Pharma, Maruho, Merck, Mitsubishi Tanabe Pharma, Moleculin, MorphoSys, Novartis, Pfizer, Prism Pharma, Promius Pharma, Prothena Biosciences, Provectus Biopharmaceuticals, Sandoz, Sun Pharmaceuticals, Takeda Pharmaceuticals, Taro Pharmaceuticals, TFS Corp, Therapeutics, UCB, Valeant Pharmaceuticals, VBL Therapeutics, XenoPort, Ziarco Pharma.


Debora White

Manager - Marketing

Ph: +1-888-789-6604

Reportstack Market Research